Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | VNN1 | O95497 | 5/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | RXRB | P28702 | 2/20 | 0.35 |
| ▸ | RXRG | P48443 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112329 | 0.87 | CES2 (0.54) | CES2RXRARXRBRXRGHDAC3 | |
| SCHEMBL540172 | 0.85 | CES1 (0.44) | CES2CES1 | |
| SCHEMBL19623264 | 0.80 | CES2 (0.42) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL12588747 | 0.78 | CES2 (0.41) | CES2GPBAR1NOTUM | |
| SCHEMBL570091 | 0.78 | CES2 (0.41) | CES2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1827001 | 0.78 | CES2 (0.54) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL21294732 | 0.77 | CES2 (0.39) | CES2VNN1RXRARXRBRXRG | |
| SCHEMBL21609818 | 0.77 | CES2 (0.48) | CES2RXRARXRBRXRGNOTUM | |
| SCHEMBL869926 | 0.76 | TAS1R3 (0.35) | CES2CES1 | |
| Water SCHEMBL1836290 | 0.76 | CES2 (0.52) | CES2VNN1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619189-B1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-2619189-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | Zoetis LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8404649-B2 | Isoxazoline oximes as antiparasitic agents | AH USA 42 LLC (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012038851-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | CES2 712/4885VNN1 1286/4885RXRA 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.